SAN DIEGO, Nov. 23 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN),
developer of advanced diagnostic products, announced today that it was issued
U.S. Patent No. 6,821,729, "Device for Molecular Biological Analysis and
Diagnostics Including Waveguides," by the U.S. Patent and Trademark Office.
The '729 patent covers methods and technologies for coupling optical
waveguides with a DNA microarray used for performing biological operations and
illuminating it at an angle that allows the size and complexity of the
diagnostic instrument to be reduced. Nanogen continues to build its patent
portfolio with the '729 patent marking the company's 78th patent issued in the
Common fluorescent detection systems utilize excitation light that arrives
at the face of a DNA chip at an angle, which requires a greater working
distance. This patent allows for new positioning of a chip's components,
including the substrate, top and edges, so that light is delivered via
integrated waveguides, thus enabling a smaller and more compact device design.
This technology also improves fluorescent detection by reducing the amount of
excitation light that is reflected back into the sensor array.
"Nanogen continues to develop technologies that allow us to reduce the
complexity and shrink the footprints of molecular diagnostic systems," said
Howard C. Birndorf, Nanogen chairman and chief executive officer. "This
intellectual property asset can be leveraged by Nanogen for potential product
development or by other innovators who, for example, are creating optical
waveguides using DNA chips and microscope slides for molecular analysis."
About Nanogen, Inc.
Nanogen's advanced diagnostics provide physicians and patients worldwide
with sophisticated information to predict, diagnose and treat disease.
Research and clinical reference labs use the highly accurate and reliable
NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarrays
and analyte specific reagents to develop tests to detect mutations associated
with genetic diseases. The next generation instrument system, the NanoChip(R)
400, is expected to be available in 2005. Nanogen's subsidiary SynX offers a
line of point-of-care diagnostic tests and is building expertise in cardiac
related health conditions. Nanogen's ten years of pioneering research
involving nanotechnology may also have future applications in medical
diagnostics, biowarfare and other industries. For additional information
please visit Nanogen's website at www.nanogen.com.
This press release contains forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements, including whether
patents owned or licensed by Nanogen will be developed into products, whether
the patents owned by Nanogen offer any protection against competitors with
competing technologies, whether Nanogen's NanoChip(R) System can be
successfully further commercialized, whether other products under development
can be successfully developed and commercialized, whether results reported by
our customers or partners can be identically replicated, whether ASRs
currently sold by Nanogen will become FDA-approved molecular diagnostic test
kits, whether Nanogen will be successful in developing additional ASRs and
protocols utilizing the NanoChip(R) System, and other risks and uncertainties
discussed under the caption "Factors That May Affect Results" and elsewhere in
Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date hereof. Nanogen disclaims any intent or obligation to update these
SOURCE Nanogen, Inc.